Vaccine immunotherapy for immune suppressed patients
A method for overcoming mild to moderate immune suppression includes the steps of inducing production of naïve T-cells and restoring T-cell immunity. A method of vaccine immunotherapy includes the steps of inducing production of naïve T-cells and exposing the naïve T-cells to endogenous or exogenous antigens at an appropriate site. Additionally, a method for unblocking immunization at a regional lymph node includes the steps of promoting differentiation and maturation of immature dendritic cells at a regional lymph node and allowing presentation of processed peptides by resulting mature dendritic cells, thus, for example, exposing tumor peptides to T-cells to gain immunization of the T-cells. Further, a method of treating cancer and other persistent lesions includes the steps of administering an effective amount of a natural cytokine mixture as an adjuvant to endogenous or exogenous administered antigen to the cancer or other persistent lesions.
1 . A method for unblocking immunization at a regional lymph node by:
promoting differentiation and maturation of immature dendritic cells in a regional lymphnode and;
allowing presentation by resulting mature dendritic cells of antigen to T-cells to gain immunization of the T-cells to the antigen.
2 . The method according to claim 1 , wherein said promoting step is further defined as administering a natural cytokine mixture (NCM) perilymphatically into lymphatics that drain into lymph nodes regional to a lesion to be treated.
3 . The method according to claim 2 , wherein the lesion is cancerous or another persistent lesion.
4 . The method according to claim 3 , wherein the presented lesion is infectious.
5 . The method according to claim 1 , wherein the antigen is an endogenous antigen.
6 . The method according to claim 1 , wherein the antigen is an exogenous antigen.
7 . The method according to claim 2 wherein said administering step is further defined as injecting the NCM perilymphatically, intralymphatically, intranodally, intrasplenically, subcuntaneously, intramuscularly or intracutaneously.
8 . A method of inducing immunization to cancer or persistent lesions by administering an effective amount of an exogenous antigen and an adjuvant consisting of a natural cytokine mixture (NCM).
9 . A method according to claim 7 , wherein said administering step is further defined as administering an NCM including IL-1, IL-2, IL-6, IL-8, δIFN and TNFα.
10 . A method according to claim 8 wherein said administering step is further defined as injecting the NCM perilymphatically, intralymphatically, intranodally, intrasplenically, subcutaneously, intramuscularly or intracutaneously.
11 . A method for unblocking immunization by overcoming mild to moderate T cell depletion and restoring T cell immune response by inducing production of naïve T cells.
12 . A method according to claim 11 , wherein said inducing step is further defined as administering a natural cytokine mixture (NCM).
13 . A method according to claim 11 wherein said administering step is further defined as injecting the NCM perilymphatically, intralymphatically, intranodally, intrasplenically, subcutaneously, intramuscularly or intracutaneously.
14 . A method according to claim 12 , wherein said administering step is further defined as injecting an NCM including IL-1, IL-2, IL-6, IL-8, δIFN and TNFα.
15 . A method according to claim 14 , wherein said administering step includes administering about 150-600 units of IL-2 per injection in the NCM.
16 . A method according to claim 11 , wherein said blocking and inducing steps are further defined as codelivering cyclophosphamide and a nonsteroidal anti-inflammatory drug (NSAID).
17 . A method of treating a cancer or other persistent lesion in an immune suppressed patient by administering an effective amount of a natural cytokine mixture as an adjuvant to endogenous or exogenously administering antigen from the cancer or persistent lesion.
18 . A method according to claim 14 , wherein said administering step is further defined as injecting an NCM including IL-1, IL-2, IL-6, IL-8, TNFα and δIFN.
19 . A method according to claim 18 , wherein said administering step is further defined as injecting an NCM including IL-1, IL-2, IL-6, IL-8, TNFα and δIFN.
20 . A method according to claim 17 , further including the steps of blocking endogenous suppression of T-cells directly or indirectly by the endogenous lesion being treated.
21 . A method according to claim 17 , wherein said blocking and inducing steps are further defined as codelivering cyclophosphamide and a nonsteroidal anti-inflammatory drug (NSAID).
22 . A method according to claim 21 , wherein the NSAIDS is selected from the group including indomethacin, ibuprofen, vioxx®-(rofecoxib), CELEBREX® (celecoxib) and other related compounds.
23 . A method of vaccine immunotherapy including the steps of:
inducing production of naïve T-cells and exposing the naïve T-cells to endogenous or exogenous antigens.
24 . A method according to claim 23 , wherein said exposing step is further defined as exposing the naïve T-cells to endogenously processed peptide preparation resident in regional nodes of a patient who possesses a lesion.
25 . A method according to claim 24 , wherein the lesion is cancerous or infectious.
26 . A method according to claim 23 , wherein said exposing step is further defined as administering an exogenously produced antigen.
27 . A method according to claim 23 , wherein said antigen is otherwise non-immunogenic peptide.
28 . A method according to claim 23 , wherein said exposing step is further defined as immunizing he naïve T-cells with matured peptide presenting dendritic cells at a lymph node distal from a lesion to be treated.
29 . A method of treating lymphocytopoenic by administering an effective amount of a natural cytokine mixture.
30 . The method according to claim 1 further including the step of stimulating naïve T-cell production.
31 . The method according to claim 1 further including the step of actuating dendritic cells to promote antigen presentation.